MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Ureter Cancer. According to GlobalData, Phase II drugs for Ureter Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MHB-036C LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MHB-036C overview

MHB-036C is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), pancreatic cancer Ductal adenocarcinoma (PDAC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), ovarian cancer (OC), carcinoma (BC), gastric cancer (GC), castration-resistant prostate cancer (CRPC) and sweat gland carcinoma (SGC), metastatic transitional (urothelial) tract cancer, ureter cancer, bladder cancer, urethral cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, metastatic ovarian cancer, triple-negative breast cancer, human epidermal growth factor receptor 2 negative breast cancer, human epidermal growth factor receptor 2 positive breast cancer, metastatic castration-resistant prostate cancer, endometrial cancer. It is being developed based on SuperTopoi ADC platform It is administered through intravenous route. It acts by  targeting TROP-2.

For a complete picture of MHB-036C’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.